Cancer cells keep dividing after normal cells age and die. It’s a secret scientists have been trying to target for decades but there’s still no successful drug in the marketplace that targets telomerase, the enzyme that keeps cancer cells dividing. Two of our researchers say new technologies and more sensitive molecular analyses mean it’s time for a fresh look. Their findings are published in Nature Reviews Cancer this month.
In their paper, Dr Greg Arndt from the ACRF Drug Discovery Centre and Dr Karen MacKenzie from our Personalised Medicine program, summarise current knowledge about telomerase As well as calling for new approaches, they suggest targeting telomerase beyond its usual role in the telomere could be key to finding the next generation of small-molecule telomerase inhibitors.
Read today’s media release.